Literature DB >> 32521140

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.

Khashayar Esfahani1, Marie Hudson1, Gerald Batist1.   

Abstract

Entities:  

Year:  2020        PMID： 32521140     DOI： 10.1056/NEJMc2002527

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

1.  Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.

Authors:  Joseph Meserve; Antonio Facciorusso; Ariela K Holmer; Vito Annese; William J Sandborn; Siddharth Singh
Journal:  Aliment Pharmacol Ther       Date:  2020-12-12       Impact factor: 8.171

2.  Immunotherapy-Mediated Luminal Gastrointestinal Toxicities.

Authors:  Anusha S Thomas; Yinghong Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events.

Authors:  James W Smithy; David M Faleck; Michael A Postow
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

Review 4.  Update on Immune Checkpoint Inhibitor Enterocolitis.

Authors:  Molly R Kelly-Goss; Yousef R Badran; Michael Dougan
Journal:  Curr Gastroenterol Rep       Date:  2022-10-20

5.  Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma.

Authors:  Hamid-Reza Moein; Brian Rutledge; Rafic Beydoun; Murray N Ehrinpreis
Journal:  Cureus       Date:  2021-04-11

6.  Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.

Authors:  Kazi J Nahar; Robert V Rawson; Tasnia Ahmed; Stephen Tattersall; Neomal Sandanayake; Christopher J Kiely; Serigne Lo; Matteo Carlino; Umaimainthan Palendira; Richard A Scolyer; Georgina V Long; Alexander M Menzies
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

Review 7.  Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.

Authors:  Sonia Victoria Del Rincón; Wilson H Miller; Meagan-Helen Henderson Berg
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

Review 8.  Immune Checkpoint Inhibitor-Induced Gastrointestinal Toxicity: The Opinion of a Gastroenterologist.

Authors:  Anca Macovei Oprescu; Raluca Tulin; Iulian Slavu; Dana Paula Venter; Constantin Oprescu
Journal:  Cureus       Date:  2021-11-27

Review 9.  Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies.

Authors:  Ryan J Sullivan; Jeffrey S Weber
Journal:  Nat Rev Drug Discov       Date:  2021-07-27       Impact factor: 112.288

10.  Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.

Authors:  Sara Hone Lopez; Gursah Kats-Ugurlu; Remco J Renken; Henk J Buikema; Marco R de Groot; Marijn C Visschedijk; Gerard Dijkstra; Mathilde Jalving; Jacco J de Haan
Journal:  Virchows Arch       Date:  2021-08-02       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.